Ginsenoside Rg3: Potential molecular targets and therapeutic indication in metastatic breast cancer
Files
(Published version)
Date
2019
Authors
Nakhjavani, M.
Hardingham, J.E.
Palethorpe, H.M.
Tomita, Y.
Smith, E.
Price, T.J.
Townsend, A.R.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Medicines, 2019; 6(1):17-1-17-20
Statement of Responsibility
Maryam Nakhjavani, Jennifer E Hardingham, Helen M Palethorpe, Yoko Tomita, Eric Smith, Tim J Price and Amanda R Townsend
Conference Name
Abstract
Breast cancer is still one of the most prevalent cancers and a leading cause of cancer death worldwide. The key challenge with cancer treatment is the choice of the best therapeutic agents with the least possible toxicities on the patient. Recently, attention has been drawn to herbal compounds, in particular ginsenosides, extracted from the root of the Ginseng plant. In various studies, significant anti-cancer properties of ginsenosides have been reported in different cancers. The mode of action of ginsenoside Rg3 (Rg3) in in vitro and in vivo breast cancer models and its value as an anti-cancer treatment for breast cancer will be reviewed.
School/Discipline
Dissertation Note
Provenance
Description
Published: 23 January 2019
Access Status
Rights
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).